SRDX (Surmodics) Cyclically Adjusted Revenue per Share: $8.45 (As of Jun. 2025)


SRDX Surmodics Inc SRDX
51 GF Score
Price $42.98
View Full Analysis

What is Surmodics Cyclically Adjusted Revenue per Share?

Surmodics SRDX -0.01% 51 Cyclically Adjusted Revenue per Share is $8.45 as of Jun. 2025. GuruFocus rates SRDX with a GF Score™ of 51/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Surmodics's adjusted revenue per share for the three months ended in Jun. 2025 was $2.070. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $8.45 for the trailing ten years ended in Jun. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-09), Surmodics's current stock price is $42.98. Surmodics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2025 was $8.45. Surmodics's Cyclically Adjusted PS Ratio of today is 5.09.


Surmodics  (NAS:SRDX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Surmodics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=42.98/8.45
=5.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Surmodics Cyclically Adjusted Revenue per Share Related Terms


Surmodics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Surmodics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surmodics Cyclically Adjusted Revenue per Share Chart

Surmodics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.32 6.02 6.86 7.57 8.10

Surmodics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.98 8.10 8.17 8.33 8.45

SRDX vs CBLL, OFIX, LAB: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Surmodics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surmodics Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Surmodics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Surmodics's Cyclically Adjusted PS Ratio falls into.


SRDX
51GF Score
Surmodics Inc SRDX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Surmodics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Surmodics's adjusted Revenue per Share data for the three months ended in Jun. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2025 (Change)*Current CPI (Jun. 2025)
=2.07/322.5610*322.5610
=2.070

Current CPI (Jun. 2025) = 322.5610.

Surmodics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201509 1.317 237.945 1.785
201512 1.254 236.525 1.710
201603 1.266 238.132 1.715
201606 1.503 241.018 2.012
201609 1.368 241.428 1.828
201612 1.321 241.432 1.765
201703 1.303 243.801 1.724
201706 1.329 244.955 1.750
201709 1.503 246.819 1.964
201712 1.302 246.524 1.704
201803 1.415 249.554 1.829
201806 1.683 251.989 2.154
201809 1.735 252.439 2.217
201812 1.609 251.233 2.066
201903 1.645 254.202 2.087
201906 1.774 256.143 2.234
201909 2.235 256.759 2.808
201912 1.643 256.974 2.062
202003 1.660 258.115 2.074
202006 1.950 257.797 2.440
202009 1.619 260.280 2.006
202012 1.631 260.474 2.020
202103 2.503 264.877 3.048
202106 1.725 271.696 2.048
202109 1.703 274.310 2.003
202112 1.658 278.802 1.918
202203 1.876 287.504 2.105
202206 1.784 296.311 1.942
202209 1.864 296.808 2.026
202212 1.783 296.797 1.938
202303 1.939 301.836 2.072
202306 3.730 305.109 3.943
202309 1.989 307.789 2.084
202312 2.167 306.746 2.279
202403 2.253 312.332 2.327
202406 2.141 314.175 2.198
202409 2.342 315.301 2.396
202412 2.103 315.605 2.149
202503 1.967 319.799 1.984
202506 2.070 322.561 2.070

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $8.45 mean?
Surmodics (SRDX) has a Cyclically Adjusted Revenue per Share of $8.45 as of Jun. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Surmodics and its competitors.
Is Surmodics' Cyclically Adjusted Revenue per Share too high?
Surmodics' current Cyclically Adjusted Revenue per Share is $8.45. Overall, Surmodics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Surmodics' Cyclically Adjusted Revenue per Share compare to CBLL and OFIX?
Surmodics' Cyclically Adjusted Revenue per Share of $8.45 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Surmodics and its competitors. Surmodics's current Cyclically Adjusted Revenue per Share is $8.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surmodics stock overvalued right now?
Surmodics (SRDX) has a current Cyclically Adjusted Revenue per Share of $8.45. The current Cyclically Adjusted Revenue per Share is $8.45. Surmodics' overall GF Score™ is 51/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Surmodics (SRDX), the current Cyclically Adjusted Revenue per Share is $8.45 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Surmodics Business Description

Address 9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
51GF Score

Get the complete analysis for SRDX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.98
Price